Technical Analysis for IMUX - Immunic, Inc.

Grade Last Price % Change Price Change
F 1.19 -1.65% -0.02
IMUX closed down 1.65 percent on Friday, November 1, 2024, on 85 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction -1.65%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 19 hours ago
60 Minute Opening Range Breakout about 23 hours ago
Up 2% about 23 hours ago
Up 1% about 23 hours ago
Down 1% about 23 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Immunic, Inc. Description

Immunic, Inc. (Nasdaq:IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORĪ³t; and IMU-856 targets the restoration of the intestinal barrier function. Immunic's lead development program, IMU-838, is in phase 2 clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional phase 2 trial in Crohn's disease planned for 2019. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is planned to start at the Mayo Clinic.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Immunotherapy Autoimmune Disease Clinical Development Multiple Sclerosis Psoriasis Ulcerative Colitis Metabolism Ulcer Abdominal Pain Colitis Crohn's Disease Molecule Product Inflammatory And Autoimmune Diseases Mayo Clinic Primary Sclerosing Cholangitis

Is IMUX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.11
52 Week Low 0.9451
Average Volume 725,058
200-Day Moving Average 1.34
50-Day Moving Average 1.49
20-Day Moving Average 1.43
10-Day Moving Average 1.34
Average True Range 0.12
RSI (14) 31.03
ADX 21.67
+DI 11.67
-DI 25.67
Chandelier Exit (Long, 3 ATRs) 1.38
Chandelier Exit (Short, 3 ATRs) 1.54
Upper Bollinger Bands 1.67
Lower Bollinger Band 1.19
Percent B (%b) 0.01
BandWidth 33.68
MACD Line -0.08
MACD Signal Line -0.05
MACD Histogram -0.0322
Fundamentals Value
Market Cap 107.02 Million
Num Shares 89.9 Million
EPS -3.25
Price-to-Earnings (P/E) Ratio -0.37
Price-to-Sales 0.00
Price-to-Book 2.27
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.27
Resistance 3 (R3) 1.27 1.26 1.25
Resistance 2 (R2) 1.26 1.24 1.25 1.25
Resistance 1 (R1) 1.22 1.23 1.22 1.22 1.24
Pivot Point 1.21 1.21 1.20 1.20 1.21
Support 1 (S1) 1.17 1.19 1.17 1.17 1.14
Support 2 (S2) 1.16 1.18 1.15 1.13
Support 3 (S3) 1.12 1.16 1.13
Support 4 (S4) 1.12